Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators

Int J Mol Sci. 2023 Mar 5;24(5):5010. doi: 10.3390/ijms24055010.

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a new series of therapeutics that correct and potentiate some classes of mutations of the CFTR, have provided a great therapeutic advantage to people with cystic fibrosis (pwCF). The main hindrances of the present CFTR modulators are related to their limitations in reducing chronic lung bacterial infection and inflammation, the main causes of pulmonary tissue damage and progressive respiratory insufficiency, particularly in adults with CF. Here, the most debated issues of the pulmonary bacterial infection and inflammatory processes in pwCF are revisited. Special attention is given to the mechanisms favoring the bacterial infection of pwCF, the progressive adaptation of Pseudomonas aeruginosa and its interplay with Staphylococcus aureus, the cross-talk among bacteria, the bronchial epithelial cells and the phagocytes of the host immune defenses. The most recent findings of the effect of CFTR modulators on bacterial infection and the inflammatory process are also presented to provide critical hints towards the identification of relevant therapeutic targets to overcome the respiratory pathology of pwCF.

Keywords: CFTR modulators; Pseudomonas aeruginosa; Staphylococcus aureus; airway epithelia; airway infection; airway inflammation; cystic fibrosis.

Publication types

  • Review

MeSH terms

  • Adult
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis* / drug therapy
  • Host-Pathogen Interactions
  • Humans
  • Lung / pathology
  • Pseudomonas aeruginosa / genetics
  • Staphylococcal Infections*

Substances

  • Cystic Fibrosis Transmembrane Conductance Regulator
  • CFTR protein, human